410 related articles for article (PubMed ID: 28208157)
1. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ
Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157
[TBL] [Abstract][Full Text] [Related]
2. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
3. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
4. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
5. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
[TBL] [Abstract][Full Text] [Related]
6. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
Hayama T; Hashiguchi Y; Okamoto K; Okada Y; Ono K; Shimada R; Ozawa T; Toyoda T; Tsuchiya T; Iinuma H; Nozawa K; Matsuda K
Int J Colorectal Dis; 2019 Aug; 34(8):1491-1496. PubMed ID: 31309326
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
8. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
9. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
10. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
[TBL] [Abstract][Full Text] [Related]
11. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
12. Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran.
Payandeh M; Shazad B; Sadeghi M; Shahbazi M
Asian Pac J Cancer Prev; 2016; 17(4):1729-32. PubMed ID: 27221845
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].
Wang Q; Zhong M; Lü YL; Yuan J; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):603-6. PubMed ID: 23157828
[TBL] [Abstract][Full Text] [Related]
14. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
[TBL] [Abstract][Full Text] [Related]
16. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
18. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
[TBL] [Abstract][Full Text] [Related]
19. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
[TBL] [Abstract][Full Text] [Related]
20. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.
Renaud S; Guerrera F; Seitlinger J; Costardi L; Schaeffer M; Romain B; Mossetti C; Claire-Voegeli A; Filosso PL; Legrain M; Ruffini E; Falcoz PE; Oliaro A; Massard G
Oncotarget; 2017 Jan; 8(2):2514-2524. PubMed ID: 27911859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]